Andrew Oxtoby is President and Chief Executive Officer of Kalaris Therapeutics, Inc. (ALVR). The company reported total compensation of $2,569,115 for fiscal year 2025.
| Salary | $537,733 |
|---|---|
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $1,687,076 |
| Non-equity incentive plan | $344,306 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $0 |
| Total | $2,569,115 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Kalaris Therapeutics, Inc. filed April 24, 2026, accession 0001193125-26-177362.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | President and Chief Executive Officer | $537,733 | $0 | $0 | $1,687,076 | $344,306 | $0 | $0 | $2,569,115 |
| FY2024 | President and Chief Executive Officer | $394,160 | $0 | $0 | $1,388,585 | $176,856 | $0 | $5,552 | $1,965,153 |
Totals as disclosed in each year's own compensation disclosure for Kalaris Therapeutics, Inc..
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Andrew Oxtoby this page | President and Chief Executive Officer | $2,569,115 |
| Matthew Feinsod | Chief Medical Officer | $1,673,771 |
| Brett Hagen | Chief Accounting Officer | $1,439,174 |
| Vikas Sinha | AlloVir's Former Chief Executive Officer, President and Chief Financial Officer | $1,100,954 |
| Matthew Gall | Former Chief Financial Officer | $1,064,607 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Kalaris Therapeutics, Inc. compensation brief.
Andrew Oxtoby's compensation sits inside Kalaris Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.